To develop the treatment, researchers first identified a unique respiratory sodium pump that delivers energy to at least 20 different types of bacteria cells and provided researchers with a new target for antibiotic treatment. Researchers then identified a compound called PEG-2S that disabled the pump mechanism. In Chlamydia trachomatis, PEG-2S restricted the pump and hindered the growth and production of the bacteria.
“The results from our collaboration are tremendously exciting,” said Pavel Dibrov, PhD, a biology professor at the University of Manitoba in Winnipeg Canada and the study’s lead author. “We are currently designing PEG-2S variations and hope to tailor PEG-based antimicrobials to each specific NQR-containing pathogenic bacterium.”
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
The compound can target the energy pump of Neisseria gonorrhoeae and Pseudomonas aeruginosa — two of the most dangerous bacterial pathogens in the world, as identified by the WHO. Further testing of PEG-2S in animals and humans is needed to fully assess the compound’s efficacy and safety, according to the report.
More articles on infection control:
CDC: Campylobacter and Salmonella primary cause of foodborne illness in 2016
Recurrent C. diff infections linked to higher death rates, research shows
Washington mumps outbreak tops 770
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
